Beijing Vigoo Biological Says EV71 Vaccine Passes Phase III Test
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
by Richard Daverman, PhD
Help employers find you! Check out all the jobs and post your resume.
by Richard Daverman, PhD
May 29, 2013 -- Beijing Vigoo Biological, a vaccine-focused subsidiary of China National Biotec Group, reported that its Enterovirus 71 vaccine was effective in up to 90% of test subjects. The company carried out a large Phase III trial in 10,245 children, aged 6 to 35 months. Half were randomized to receive vaccine. EV71, which strikes mainly children under the age of five, is a major cause of hand, foot and mouth disease. More details....
Help employers find you! Check out all the jobs and post your resume.